Clinical Trials Browser

Phase 1 × Recurrence × Alemtuzumab × Clear all

NCT05557903 2022-09-28

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Phase 1 Unknown

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT00923182 2015-04-30

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell